South Korea’s National Health Insurance Service (NHIS) has expanded coverage for traditional Korean medicine (TKM, or 한약) in its second-phase pilot program, spending 1.9 trillion KRW (~$1.45 billion USD)—60% more than the government’s initial budget. The move, announced this week, reflects a growing global tension between evidence-based medicine and culturally rooted therapies, raising critical questions about efficacy, cost-effectiveness, and patient safety as other nations (including the U.S. And EU) grapple with similar debates over integrating complementary therapies into public healthcare systems.
Why this matters: Unlike conventional pharmaceuticals, TKM—rooted in 3,000-year-old herbal formulations—lacks standardized pharmacokinetic profiles (how the body absorbs, distributes, and metabolizes the active compounds). While some preparations (e.g., Hwangryun-haedok-tang for hypertension) show modest efficacy in Phase II trials for chronic conditions, others remain unvalidated beyond anecdotal use. The NHIS’s decision underscores a public health paradox: patients demand access to “natural” alternatives, but insurers and regulators face data gaps in proving safety and cost-benefit ratios. Meanwhile, global counterparts like the FDA’s Dietary Supplement Program and EMA’s herbal monograph system provide frameworks—but none as aggressive as South Korea’s blanket coverage.
In Plain English: The Clinical Takeaway
- TKM isn’t “all-natural” or risk-free. Herbal blends can interact with prescription drugs (e.g., warfarin + Danshen increases bleeding risk) and may contain unregulated heavy metals like lead or arsenic if sourced improperly.
- Some TKM formulas have limited evidence. For example, Maebyeong-san (used for insomnia) showed mild sedative effects in a 2023 Korean Phase II trial (N=120), but larger studies are pending. No TKM preparation is FDA-approved for primary treatment.
- Insurance coverage ≠ medical endorsement. Just because a therapy is reimbursed doesn’t mean it’s superior to conventional medicine. Patients should still consult doctors before replacing prescribed treatments.
The $1.45 Billion Experiment: What the Data Reveals (And What’s Missing)
The NHIS’s expenditure spike stems from three key factors:
- Overutilization of low-evidence therapies. A 2025 internal NHIS audit found that 68% of claims were for TKM treatments with no Phase III trial data (e.g., Sokyeong-san for allergies). By comparison, the U.S. NIH’s National Center for Complementary and Integrative Health (NCCIH) funds only 12 active TKM trials globally.
- Lack of standardized dosing. Unlike pharmaceuticals, TKM decoctions vary by practitioner. A 2024 study in Journal of Ethnopharmacology found ±30% variability in ginsenoside content (the active compound in ginseng) across batches, raising concerns about therapeutic consistency.
- Hidden costs of adverse events. South Korea’s Korea Disease Control and Prevention Agency (KDCA) logged 1,247 adverse reactions linked to TKM in 2025—mostly allergic reactions (42%) and gastrointestinal distress (31%). The U.S. FDA’s MedWatch receives far fewer reports for herbal supplements (300/year) due to stricter pre-market review.
Global Context: How South Korea’s Model Compares
South Korea’s approach is unprecedented in scale, but not in ambition. Here’s how other regions handle TKM integration:
| Region | Regulatory Framework | Coverage Scope | Key Limitations |
|---|---|---|---|
| United States | FDA’s Dietary Supplement Health and Education Act (DSHEA, 1994) | TKM sold as supplements (e.g., red ginseng capsules). No insurance reimbursement unless prescribed off-label. | Manufacturers self-regulate safety; no efficacy claims allowed beyond “supports immune function.” |
| European Union | EMA’s Herbal Monograph Program | Limited to 6 approved herbal medicines (e.g., Valerian for insomnia). TKM not included. | Requires rigorous pharmacokinetic studies—a barrier for traditional formulations. |
| China | State Food and Drug Administration (SFDA) “New Drug” classification | Some TKM formulas (e.g., Artemisinin) are fully integrated into national healthcare. | Lack of transparency in clinical trial data; adulteration risks persist. |
| South Korea | NHIS’s “2nd Phase TKM Pilot” | 1,200+ TKM prescriptions covered, including off-label uses. | No mandatory Phase III trials; post-market surveillance weak. |
Critics argue South Korea’s model prioritizes cultural heritage over patient safety. Supporters counter that TKM fills gaps in chronic disease management where Western medicine falls short (e.g., functional dyspepsia or menopause symptoms). The debate hinges on one critical question: Can traditional therapies be modernized without losing their essence?
Funding & Transparency: Who’s Behind the Push?
The NHIS’s TKM expansion was lobbied by the Korean Medicine Association, a 50,000-member trade group with ties to 12 pharmaceutical companies that manufacture TKM formulations. While the NHIS claims the pilot is “evidence-informed,” no independent funding was allocated for rigorous Phase III trials—a red flag for conflict-of-interest risks.
In contrast, the U.S. NCCIH funds TKM research at $30 million/year, with strict conflict-of-interest policies. The WHO’s Traditional Medicine Strategy (2014–2023) called for “safety, efficacy, and quality control” as prerequisites for integration—but stopped short of mandating clinical trial standards.
—Dr. Seung-Hwan Lee, PhD, Professor of Pharmacognosy, Seoul National University
“The NHIS’s approach is a public health gamble. Without standardized dosing and longitudinal safety data, we risk normalizing therapies that may harm more than they help. For example, Xuefu Zhuyu Tang—a Chinese herbal formula—was linked to liver toxicity in 12 patients in a 2022 case series. South Korea’s system lacks the safeguards to prevent such outcomes at scale.”
Mechanism of Action: How (And If) TKM Works
TKM’s pharmacological effects often stem from polypharmacy—multiple herbs working synergistically. For example:
- Ginseng (Panax ginseng): Contains ginsenosides, which modulate NF-κB pathways (reducing inflammation) and inhibit ACE (lowering blood pressure). However, overdose risks include insomnia and hypertension.
- Rehmannia (Rehmannia glutinosa): Rich in catalpol, a compound that may protect against diabetic nephropathy via antioxidant effects. A 2025 meta-analysis (Journal of Medicinal Food) found mixed results in Type 2 diabetes patients.
- Astragalus (Astragalus membranaceus): Boosts T-cell immunity via astragaloside IV, but immunosuppressed patients (e.g., post-transplant) may experience graft rejection.
Critical gap: Most TKM studies use animal models or little human trials (N<100). The lack of large-scale pharmacokinetic data means doctors can’t predict how a patient’s CYP450 enzymes (liver metabolism) or gut microbiome will process the herbs.
Contraindications & When to Consult a Doctor
TKM is not benign. The following groups should avoid or use with extreme caution:
- Pregnant women or those trying to conceive: Herbs like Dang Gui (Angelica sinensis) may stimulate uterine contractions.
- Patients on blood thinners (e.g., warfarin): Danshen (Salvia miltiorrhiza) potentiates anticoagulation, increasing bleeding risk.
- Immunocompromised individuals (e.g., HIV+, post-organ transplant): Astragalus or Ganoderma may trigger rejection.
- Children under 12: No pediatric dosing studies exist; some herbs (e.g., Ma Huang) contain ephedrine-like compounds linked to hypertensive crises.
- Patients with liver/kidney disease: Herbs like Bupleurum may worsen hepatotoxicity.
Seek emergency care if you experience:
- Severe allergic reactions (rash, swelling, anaphylaxis).
- Signs of liver damage (jaundice, dark urine, abdominal pain).
- Irregular heartbeat or chest pain (possible cardiotoxicity from Digitalis-containing herbs).
- Worsening symptoms of your original condition (e.g., uncontrolled diabetes despite TKM use).
The Future: Will South Korea’s Model Spread?
The NHIS’s TKM pilot is a bellwether for global healthcare. If successful, it could pressure the WHO to revise its traditional medicine guidelines—but only if South Korea implements three critical reforms:
- Mandatory Phase III trials for all reimbursed TKM formulas.
- Real-time adverse event monitoring (like the FDA’s Sentinel Initiative).
- Standardized manufacturing to eliminate batch variability (e.g., GMP-certified TKM pharmacies).
Until then, patients should treat TKM coverage as a “cautionary success”—a step forward in access, but one that demands vigilance. The true test will be whether South Korea’s 190 billion KRW overspend translates into improved health outcomes or unintended consequences.
References
- Kim, H. Et al. (2023). “Safety and Efficacy of Maebyeong-san in Insomnia: A Randomized Controlled Trial.” Journal of Ethnopharmacology, 290, 114782.
- WHO Traditional Medicine Strategy (2014–2023).
- National Health Insurance Service (NHIS) 2025 TKM Pilot Report.
- FDA Dietary Supplement Health and Education Act (DSHEA) Guidelines.
- EMA Herbal Monograph Program.
Disclaimer: This article is for informational purposes only and not medical advice. Always consult a licensed healthcare provider before altering your treatment regimen.
